Johnson & Johnson (JNJ)

Johnson & Johnson (JNJ) Healthcare & Pipeline Overview

Johnson & Johnson, a diversified healthcare giant, operates through its Innovative Medicine and MedTech segments. Following the Kenvue spin-off, JNJ focuses on prescription drugs for complex diseases and advanced medical technologies, leveraging its established global presence and research capabilities to serve diverse healthcare needs.

What Is the Investment Thesis for JNJ?

Johnson & Johnson presents a compelling investment case centered on its strategic focus on high-growth Innovative Medicine and MedTech segments following the Kenvue spin-off. With a market capitalization of $639.31B and a profit margin of 21.8%, JNJ demonstrates financial stability. Key value drivers include its robust pipeline of pharmaceutical products targeting complex diseases and its diverse portfolio of medical devices. Upcoming FDA approvals for novel therapies and expansion into emerging markets represent significant growth catalysts. However, potential risks include patent expirations, regulatory challenges, and competition from other healthcare companies. The company's dividend yield of 2.35% provides an additional incentive for investors.

Based on FMP financials and quantitative analysis

JNJ Key Highlights

• Market capitalization of $639.31B reflects JNJ's significant presence in the healthcare industry.
• Profit margin of 21.8% indicates strong profitability and efficient operations.
• Gross margin of 69.1% showcases JNJ's ability to maintain high pricing power and manage costs effectively.
• Dividend yield of 2.35% provides a steady income stream for investors.
• Beta of 0.33 suggests lower volatility compared to the overall market, making it a relatively stable investment.

Who Are JNJ's Competitors?

JNJ is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are JNJ's Key Strengths?

• Diversified revenue streams across pharmaceuticals and medical devices.
• Strong financial performance and profitability.
• Extensive global presence and distribution network.
• Robust research and development capabilities.

What Are JNJ's Weaknesses?

• Exposure to patent expirations and generic competition.
• Regulatory risks and compliance challenges.
• Potential for product liability litigation.
• Dependence on key products for revenue generation.

What Could Drive JNJ Stock Higher?

• FDA approvals for novel pharmaceutical products in oncology and immunology.
• Expansion of MedTech portfolio through strategic acquisitions and partnerships.
• Increased investment in research and development to drive future product innovation.
• Geographic expansion in emerging markets to tap into growing healthcare demand.

What Are the Key Risks for JNJ?

• Rich valuation — a P/E of 29.2 runs well above the Healthcare sector’s ~23x, leaving little room for a miss.
• Insider selling — insiders were net sellers of roughly $4.9M recently.
• Patent expirations for key pharmaceutical products, leading to generic competition.
• Regulatory challenges and compliance issues related to product safety and efficacy.
• Litigation risks associated with product liability claims.
• Pricing pressures and reimbursement challenges from healthcare payers.
• Economic downturns and market volatility impacting healthcare spending.

What Are the Growth Opportunities for JNJ?

• Expansion in Emerging Markets: Johnson & Johnson has a significant opportunity to expand its presence in emerging markets, where healthcare spending is increasing rapidly. By leveraging its established infrastructure and product portfolio, JNJ can tap into the growing demand for pharmaceuticals and medical devices in regions such as Asia-Pacific and Latin America. This expansion can drive revenue growth and diversify JNJ's geographic footprint. The emerging markets healthcare sector is projected to reach $1.7 trillion by 2030.
• Innovative Medicine Pipeline: Johnson & Johnson's robust pipeline of pharmaceutical products represents a significant growth opportunity. The company is developing novel therapies for a range of diseases, including cancer, autoimmune disorders, and infectious diseases. Successful clinical trials and regulatory approvals for these products can drive revenue growth and enhance JNJ's market position. The global oncology market is projected to reach $286.6 billion by 2031.
• MedTech Innovation: Johnson & Johnson's MedTech segment is focused on developing innovative medical devices and solutions. The company is investing in areas such as robotic surgery, digital health, and personalized medicine. These innovations can improve patient outcomes, reduce healthcare costs, and drive revenue growth. The global medical device market is projected to reach $671.49 billion by 2030.
• Strategic Acquisitions and Partnerships: Johnson & Johnson can pursue strategic acquisitions and partnerships to expand its product portfolio, access new technologies, and enter new markets. By acquiring companies with complementary capabilities, JNJ can strengthen its competitive position and accelerate growth. The company has a track record of successful acquisitions, and this strategy can continue to drive value creation.
• Focus on Personalized Medicine: Johnson & Johnson is increasingly focused on personalized medicine, which involves tailoring treatments to individual patients based on their genetic and molecular characteristics. By developing diagnostic tools and targeted therapies, JNJ can improve treatment outcomes and reduce side effects. This approach can drive revenue growth and differentiate JNJ from its competitors. The global personalized medicine market is projected to reach $4.1 trillion by 2030.

What Opportunities Does JNJ Have?

• Expansion in emerging markets.
• Development of innovative therapies and medical devices.
• Strategic acquisitions and partnerships.
• Growth in personalized medicine.

What Threats Does JNJ Face?

• Increasing competition from other healthcare companies.
• Pricing pressures and reimbursement challenges.
• Changes in healthcare regulations and policies.
• Economic downturns and market volatility.

What Are JNJ's Competitive Advantages?

• Strong brand reputation and recognition.
• Extensive global distribution network.
• Robust research and development capabilities.
• Diversified product portfolio across pharmaceuticals and medical devices.
• Significant patent protection for key products.

What Does JNJ Do?

Founded in 1886, Johnson & Johnson has evolved into a global healthcare leader. Initially focused on sterile surgical dressings, the company expanded its portfolio to include pharmaceuticals, medical devices, and consumer health products. A pivotal strategic shift occurred in 2023 when Johnson & Johnson divested its Consumer Health division into a separate entity, Kenvue Inc. This separation allowed JNJ to concentrate on its higher-growth Innovative Medicine and MedTech segments. The Innovative Medicine segment develops and markets prescription medications for a range of conditions, including rheumatoid arthritis, cancer, HIV/AIDS, and neurodegenerative disorders. Key products in this segment address significant unmet medical needs and represent a substantial portion of JNJ's revenue. The MedTech segment offers a diverse array of medical devices and solutions, including electrophysiology products, neurovascular care, orthopaedics (hips, knees, spine), advanced surgery solutions, and ACUVUE contact lenses. These products serve a broad spectrum of healthcare providers and patients globally. Johnson & Johnson's products are distributed through hospitals, healthcare professionals, wholesalers, and retailers, reaching patients and consumers worldwide. The company maintains a strong commitment to research and development, investing heavily in innovation to drive future growth and address evolving healthcare challenges. Headquartered in New Brunswick, New Jersey, Johnson & Johnson continues to build upon its legacy of advancing human health through innovative products and solutions.

What Products and Services Does JNJ Offer?

• Researches and develops pharmaceutical products.
• Manufactures and sells pharmaceutical products.
• Develops and markets medical devices.
• Offers products for electrophysiology.
• Provides neurovascular care products.
• Offers orthopaedic solutions for hips, knees, and spine.
• Provides advanced surgery solutions.
• Manufactures and sells disposable contact lenses under the ACUVUE brand.

How Does JNJ Make Money?

• Develops and patents innovative pharmaceutical products.
• Manufactures and distributes pharmaceutical products and medical devices globally.
• Generates revenue through sales to hospitals, healthcare professionals, wholesalers, and retailers.
• Invests heavily in research and development to drive future product innovation.

What Industry Does JNJ Operate In?

Johnson & Johnson operates in the highly competitive pharmaceutical and medical device industries. The global pharmaceutical market is driven by factors such as an aging population, increasing prevalence of chronic diseases, and advancements in medical technology. The medical device market is experiencing growth due to technological innovations, rising demand for minimally invasive procedures, and increasing healthcare expenditure. Johnson & Johnson competes with other major players such as ABBV: AbbVie Inc., UNH: UnitedHealth Group Incorporated, AZN: AstraZeneca PLC, NVS: Novartis AG, and MRK: Merck & Co., Inc., all vying for market share through product innovation, strategic partnerships, and global expansion.

Who Are JNJ's Key Customers?

• Hospitals and healthcare systems.
• Healthcare professionals (doctors, nurses, surgeons).
• Wholesalers and distributors of pharmaceutical and medical products.
• Retail pharmacies and drugstores.
• Patients and consumers who use JNJ's products.

Net sellingInsider Activity

Over the past six months, Johnson & Johnson insiders filed 15 SEC Form 4 transactions — 4 sales and 11 purchases. On net that is roughly 13K shares disposed (about $4.9M), a signal worth weighing alongside the fundamentals.

FY2026 estForward Outlook

Wall Street analysts project Johnson & Johnson revenue of about $101.03B for fiscal 2026, with EPS near $11.59. The estimate reflects 17 contributing analysts.

F-Score 7/9Financial Health

Johnson & Johnson's Piotroski F-Score is 7/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 5.31 places it in the safe zone, indicating low near-term bankruptcy risk.

ROE 26%Key Financial Metrics

Return on equity for Johnson & Johnson stands at 26.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 10.5%, showing how much profit it generates from its asset base. JNJ trades at a trailing price-to-earnings ratio of 29.23, above the Healthcare sector average of ~23x. Its free cash flow yield is 2.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.03 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 3.4%, the inverse of the P/E and a quick read on earnings relative to price.

Johnson & Johnson (JNJ) Valuation Context

Valued at $639.31B, JNJ is classified as a mega-cap stock. Relative to its peer group, JNJ's quantitative score of 91/100 is above the peer average of 71/100.

Company Profile

Johnson & Johnson operates in the Drug Manufacturers - General industry within the Healthcare sector. It is headquartered in New Brunswick, US. The company is led by CEO Joaquin Duato. JNJ has traded publicly since 1943.

JNJ Financials

JNJ Latest News

JNJ Analyst Consensus

JNJ MoonshotScore

Latest Johnson & Johnson Analysis

JNJ Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources